Is Alcohol Good, Bad, or Neutral for Cardiovascular Health?

In the 2018 Guidelines on Hypertension, commandment no. 6 states that we should make lifestyle interventions such as sodium restriction, healthy eating, regular exercise, weight control, and smoking cessation, and also alcohol moderation.

¿El alcohol es bueno, malo o neutro para la salud cardiovascular?It is clear that heavy alcohol consumption induces hypertension and may probably be one of the main causes of secondary hypertension, but few sources detail what a moderate or “healthy” consumption is.

There are consistent observational data to indicate that there is an association between alcohol use and cardiovascular events, and that, as a whole, it is U-shaped. In other words, low or moderate alcohol consumption (up to one drink or 12.5 g alcohol per day in women and up to two drinks or 25 g per day in men) are associated with a reduced risk of overall cardiovascular events and mortality, compared with absolute abstinence or excessive consumption.


Read also: Progress of patients with hypertrophic cardiomyopathy treated with alcohol septal ablation.


The alcohol content of a beverage is expressed in degrees and it measures the content of absolute alcohol in 100 cm3, i.e. the alcohol percentage in a beverage. For example, if we have a 13-degree wine, that means that it contains 13 cm3 of absolute alcohol for every 100 cm3 of wine. In product labels, alcoholic content is expressed as (°) or vol%. The calculation would be as follows: consumed volume (in cm3) × alcohol content × 0.8, and then divide all by 100. We must ask the patient about the type of beverage (so as to get the alcohol content) and the amount consumed (so as to get the volume, in cm3) in order to calculate whether such consumption is good or bad for their health.

In any case, this generalization masks important aspects that merit closer examination.

Patterns of drinking, the type of alcohol consumed, and factors associated with alcohol consumption, such as socio-economic status and dietary patterns, may modify significantly such generalization. Well-established cardiac disease also implies differences, particularly for patients with left ventricular dysfunction.


Read also: Alcohol dilemma: Cardiovascular enjoyment and benefits versus cancer.


Furthermore, the effects of alcohol on coronary pathologies may differ from its effects on arrhythmias or heart failure risk, and they may also differ on ischaemic stroke and intracerebral haemorrhage.

It is important to consider that even if there is a modest cardiovascular benefit derived from moderate consumption, it may imply a risk of cancer and cirrhosis.

Finally, the data supporting this modest benefit have emerged from observational studies that are subject to many methodological limitations and potential confounding variables.


Read also: MitraClip in the “Real World”.


Consequently, for the time being, it may be better to advise restraint as opposed to support consumption to reduce cardiovascular risk.

leong2019-libre-para-publicar

Original title: Are the Cardiac Effects of Alcohol Good, Bad, or Neither?

Reference: Leong DP et al. Eur Heart J. 2019 Mar 1;40(9):712-714.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...